Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Reference Guide
  /  
H. pylori Virulence Factor babA
Sign up free to test for 
H. pylori Virulence Factor babA
.
One login for 30+ lab companies.

H. pylori Virulence Factor babA

Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that infects the stomach lining, causing chronic gastritis, peptic ulcers, and increasing the risk of gastric lymphoma and carcinoma. 

It is one of the most common chronic bacterial infections worldwide, affecting up to 50% of the global population, with higher prevalence in developing countries. 

H. pylori is typically acquired in early childhood and can persist without treatment. The bacterium's ability to survive in the acidic environment of the stomach is attributed to various virulence factors. 

Its high mutation and recombination rates lead to extensive strain diversity. 

While many infected individuals remain asymptomatic, H. pylori can cause symptoms such as abdominal pain, nausea, vomiting, and dyspepsia when gastritis or peptic ulcer disease develops. 

Diagnosis involves non-invasive methods like urea breath tests and stool antigen tests, and invasive methods such as endoscopic biopsy.   Treatment generally includes a combination of proton pump inhibitors and antibiotics. 

The BabA (blood group antigen binding adhesin) is a major outer membrane protein virulence factor of Helicobacter pylori, encoded by the babA2 gene.  It binds to the Lewis b (Leb) blood group antigen expressed on gastric epithelial cells, facilitating the attachment and colonization of H. pylori in the gastric mucosa. 

Expression of BabA is associated with an increased risk of developing severe gastric diseases like peptic ulcers, atrophic gastritis, and gastric adenocarcinoma.

What is H. Pylori?  [8., 9.]

Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that infects the stomach lining and is a common cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma. 

It affects up to 50% of the global population, with higher prevalence in developing countries.  It is one of the most common chronic bacterial infections worldwide.

H. pylori is typically acquired in early childhood and persists without treatment. 

It is able to survive in the harsh acidic environment of the stomach due to its unique features like flagella for motility and urease enzyme production.

Its genome exhibits high mutation and recombination rates, leading to extensive strain diversity.  [8., 11.] 

While many infected individuals remain asymptomatic, the bacteria can cause symptoms such as abdominal pain, nausea, vomiting, and dyspepsia once gastritis or peptic ulcer disease develops.   H. pylori infection causes chronic gastritis in all cases and increases the risk of peptic ulcers by 2-6 fold and gastric cancer by 2-6 fold compared to uninfected individuals.  [4., 8.] 

Transmission occurs through fecal-oral, oral-oral, and gastric-oral routes, with lower socioeconomic status being a significant risk factor.  

Diagnosis involves both non-invasive methods like urea breath tests and stool antigen tests, and invasive methods such as endoscopic biopsy. 

Treatment often includes a combination of proton pump inhibitors and antibiotics.  Antibiotic combination therapies like clarithromycin triple therapy or bismuth quadruple therapy may be used.  [4.]  

Early identification and treatment of H. pylori infections are crucial to prevent serious gastrointestinal diseases and potential malignancies.  Collaboration among healthcare professionals is essential for effective management and improved patient outcomes.

What are H. pylori Virulence Factors?  [1., 3., 6.] 

H. pylori virulence factors refer to the various bacterial components and mechanisms that enable the pathogen Helicobacter pylori to successfully colonize the human stomach, evade the host's immune defenses, and cause associated diseases and complications.

Colonization Factors

  • Urease enzyme: allows H. pylori to survive in the acidic environment of the stomach by producing ammonia to neutralize gastric acid
  • Flagella and chemotaxis: enables motility and directed movement towards the gastric epithelium for colonization

Adhesins:

  • BabA (Blood group antigen binding adhesin): binds to Lewis b antigens on gastric epithelial cells
  • SabA (Sialic acid-binding adhesin): binds to sialyl-Lewis x antigens
  • OipA (Outer inflammatory protein A): promotes inflammation and IL-8 production
  • Vacuolating cytotoxin (VacA): induces vacuolation and apoptosis in gastric epithelial cells
  • Cag Pathogenicity Island (cagPAI):
  • Encodes a type IV secretion system (T4SS) to inject the CagA effector protein into host cells
  • CagA disrupts signaling pathways, causing cytoskeletal rearrangements and increased inflammation 

Other Factors

  • IceA (Induced by contact with epithelium): upregulated upon adherence, increases mucosal injury
  • DupA (Duodenal ulcer promoting gene A): associated with increased duodenal ulcer risk
  • GGT (Gamma-glutamyl transpeptidase): helps H. pylori persist by metabolizing glutamine and glutathione

H. pylori Virulence Factor babA

The BabA (blood group antigen-binding adhesin) is an H. pylori virulence factor important in the initial attachment and colonization of H. pylori in the gastric mucosa.  It facilitates the establishment of persistent infection by binding to the Lewis b (Leb) and related antigens expressed on the gastric epithelial cells.

Definition of Virulence Factor babA

BabA is an outer membrane protein that belongs to the family of outer membrane proteins (OMPs) in H. pylori.  It is encoded by the babA2 gene and functions as an adhesin, enabling the bacterium to adhere to the gastric epithelial cells.  [3.]

Expression of babA is associated with an increased risk of developing severe gastric diseases such as peptic ulcers, atrophic gastritis, and gastric adenocarcinoma.  [3., 10.] 

The prevalence of babA2-positive H. pylori strains varies geographically, with higher rates observed in regions with a high incidence of gastric cancer, such as East Asia.  [7., 10.] 

Testing for the presence of babA2 gene or babA expression can be useful in identifying individuals at higher risk for developing H. pylori-associated diseases, particularly in high-risk populations. 

Mechanism of Action in H. pylori Pathogenesis

BabA binds to the Lewis b (Leb) blood group antigen expressed on the surface of gastric epithelial cells, facilitating the attachment and colonization of H. pylori

This binding allows the bacteria to resist the shedding forces of the gastric mucosa and establish persistent colonization.  [3., 7.]

BabA may act synergistically with other virulence factors like CagA and VacA to enhance the pathogenicity of H. pylori and disease progression.  [7., 10.] 

For example, BabA enhances the translocation of the effector protein CagA into host cells, leading to cellular damage and inflammation.  [1.] 

Association with Severe Gastric Diseases and Clinical Outcomes

Several studies have demonstrated a strong association between the presence of the BabA virulence factor and the development of severe gastric diseases.  H. pylori strains expressing BabA have been linked to an increased risk of peptic ulcer disease, gastric cancer, and other gastric complications.  [1., 3., 10.]

Additionally, the expression of BabA has been correlated with specific clinical outcomes, such as the severity of gastric inflammation and the development of precancerous lesions.  [3.] 

Studies have shown that strains with low BabA expression (BabA-L) are linked to the highest risk of gastric cancer, followed by high BabA expression (BabA-H) strains.  [3.] 

Strains that are "triple-positive" for cagA, vacA s1, and babA2 show a significantly higher risk for severe clinical outcomes such as peptic ulcer and gastric adenocarcinoma.  [3.] 

Correlation with ABO Blood Groups and Disease Susceptibility

Interestingly, studies have shown a correlation between the presence of BabA and specific ABO blood groups, suggesting a potential link between host genetic factors and disease susceptibility. 

BabA-positive H. pylori strains can be classified as "specialists," which bind only blood group O-specific glycans, or "generalists," which bind glycans of blood groups O, A, and B.

Individuals with blood group O may be more prone to developing severe gastric diseases when infected with BabA-positive H. pylori strains.  [2.]  This information can aid in identifying high-risk individuals and implementing targeted preventive measures.

Laboratory Testing for H. pylori Virulence Factor babA

Test Information, Sample Collection and Preparation

Laboratory testing for H. pylori virulence factors typically involves a stool sample, which is tested via polymerase chain reaction (PCR) for H. pylori virulence factors.

The stool sample may be collected at home.  While special preparation is not typically required for this assessment, other test components may require special preparation such as avoidance of certain foods, supplements or medications.

Click here to discover a laboratory test that assesses for H. pylori and virulence factors.  

Interpretation of Test Results

Optimal Levels of H. pylori Virulence Factor babA

H. pylori infections can cause serious conditions including peptic ulcer disease and gastric cancer, and the presence of virulence factors such as the babA virulence factor can increase the risk of developing serious disease.  

Optimal levels of H. pylori virulence factor babA are undetectable.

Clinical Significance of Elevated H. pylori Virulence Factor babA

A positive test result indicates the presence of H. pylori and the virulence factor babA, which requires prompt treatment.  

Treatments for H. pylori Infection

Typical first-line eradication therapies may include medications such as clarithromycin, bismuth, amoxicillin, metronidazole, or tetracycline in combination, along with a PPI.

The presence of babA-positive strains may indicate the need for more intensive therapies, including anti-adhesion compounds.  [1., 7.] 

With the increase in antibiotic resistance demonstrated by H. pylori, especially in the setting of virulence factor-positive strains, scientists are exploring alternative methods of treating H. pylori including botanical therapies.  Some botanical compounds that have shown promise in treating H. pylori include:  [5.] 

Terpenoids:

  • Monoterpenoids: compounds like limonene and β-pinene promote mucus secretion, reduce oxidative stress and inflammation, and inhibit NF-κB expression.
  • Limonene can be found in the peels and essential oils of oranges, lemons, limes, grapefruits, and mandarins as well as dill, caraway, mint and parsley.
  • Beta-pinene is a component of pine resin and is also found in various plants and herbs. Common sources include basil, parsley, rosemary, sage, as well as pine trees, fir trees, and other coniferous trees.
  • Sesquiterpenoids: found in cedarwood essential oil, they inhibit urease activity and H. pylori growth.
  • Triterpenoids: glycyrrhizic acid, found in Glycyrrhiza glabra or licorice, shows rapid anti-H. pylori properties.
  • Tetraterpenoids: Carotenoids like β-carotene and astaxanthin demonstrate antioxidant properties and reduce oxidative stress-mediated inflammation.
  • Beta-carotene is found in carrots, sweet potatoes, pumpkin, butternut squash, spinach, kale, collard greens, swiss chard, red and yellow peppers; mangoes, cantaloupe, apricot, papaya, peaches; cilantro, and parsley.  
  • Astaxanthin is found in seafood, some algae, and in supplement form.

Polyphenols:

  • Flavonoids: compounds like kaempferol and myricetin inhibit H. pylori growth, reduce urease activity, and exert anti-inflammatory effects.
  • Kaempferol can be found in many foods and essential oils including leafy greens, cruciferous vegetables such as broccoli, brussels sprouts and cabbage; herbs including dill, chives and tarragon; berries, capers and beans.  
  • Myricetin can be found in berries, especially cranberries; grapes, pomegranates, onions, kale, spinach, parsley, thyme, and walnuts.  
  • Tannoids: these compounds damage the bacterial membrane and reduce nitric oxide levels, exerting anti-inflammatory effects.

Alkaloids:

  • Berberine and Coptisine: these alkaloids inhibit urease activity and disrupt bacterial cell membranes, enhancing the effects of antibiotics.
  • Curcumin: curcumin, derived from turmeric, has shown efficacy in reducing H. pylori colonization, modulating immune responses, and improving symptoms of dyspepsia.

Related Biomarkers for H. pylori Virulence Factor babA

In addition to the BabA virulence factor, several other biomarkers have been identified and studied in the context of H. pylori infection and associated gastric diseases.

CagA Virulence Factor and its Role in Gastric Cancer  [1., 3.]

The cytotoxin-associated gene A (CagA) is a major virulence factor of H. pylori that has been extensively studied for its role in gastric cancer development. 

The presence of CagA has been strongly associated with an increased risk of gastric cancer.  

VacA Virulence Factor and its Association with Peptic Ulcers  [3.] 

The vacuolating cytotoxin A (VacA) is another important virulence factor of H. pylori that contributes to the pathogenesis of peptic ulcers.  VacA induces the formation of vacuoles in gastric epithelial cells, leading to cellular damage and disruption of the gastric mucosal barrier. 

The presence of the vacA gene and its specific allelic variations have been linked to an increased risk of peptic ulcer disease and gastric inflammation.

Serological Biomarkers (Anti-H. pylori Antibodies)

In addition to bacterial virulence factors, serological biomarkers such as anti-H. pylori antibodies can also be used for the diagnosis and monitoring of H. pylori infection. 

These antibodies are produced by the host's immune system in response to the bacterial antigens and can be detected in serum or plasma samples.

Clinical Utility of BabA Testing

Potential Use in Risk Stratification and Disease Management

The presence of the BabA virulence factor has been associated with an increased risk of severe gastric diseases, such as peptic ulcers and gastric cancer.  

By testing for BabA, clinicians can stratify patients based on their risk profile and tailor management strategies accordingly.  Patients with BabA-positive H. pylori strains may require more intensive monitoring and early intervention to prevent disease progression.

Integration with Other Biomarkers for Improved Diagnostic Accuracy

While BabA testing provides valuable information, it is often combined with other biomarkers, such as CagA and VacA, to enhance diagnostic accuracy and better understand the pathogenic potential of H. pylori strains. 

By integrating multiple virulence factors and host factors, clinicians can gain a more comprehensive understanding of the infection and tailor treatment strategies accordingly.

FAQ: H. pylori Virulence Factor babA

What is H. pylori?

Helicobacter pylori (H. pylori) is a type of bacteria that infects the stomach lining and is a common cause of peptic ulcers, chronic gastritis, and is associated with an increased risk of stomach cancer.

What is a virulence factor?

A virulence factor is a molecule produced by a pathogen (such as bacteria, viruses, fungi, and protozoa) that enables it to achieve colonization, immunoevasion, and immunosuppression within the host, and to cause disease.

What is babA?

babA (blood group antigen-binding adhesin) is a specific virulence factor produced by H. pylori. It is a protein that allows the bacteria to adhere to the stomach lining by binding to the Lewis b blood group antigens on the surface of stomach epithelial cells.

Why is babA significant in H. pylori infections?

babA is significant because it enhances the ability of H. pylori to colonize and persist in the stomach lining. 

This strong adhesion facilitates the bacteria's survival in the acidic environment of the stomach and contributes to its pathogenicity, leading to more severe inflammation and an increased risk of developing ulcers and stomach cancer.

How is babA detected in H. pylori?

BabA can be detected through molecular testing methods such as PCR (polymerase chain reaction) and sequencing, which identify the presence of the babA gene in H. pylori samples. Additionally, immunological assays can detect the babA protein.

What are the implications of having H. pylori with the babA virulence factor?

Infections with H. pylori strains that express the babA virulence factor are often more severe. These strains are more adept at adhering to the stomach lining, leading to higher levels of inflammation, increased ulcer formation, and a greater risk of gastric cancer.

How is an H. pylori infection with babA treated?

The treatment for an H. pylori infection with the babA virulence factor is similar to treatment for other H. pylori infections, typically involving a combination of antibiotics and acid-suppressing medications. 

However, understanding the presence of babA can help healthcare providers anticipate a potentially more aggressive infection and tailor treatment accordingly.

Can lifestyle changes help manage H. pylori infections?

While antibiotics are necessary to eradicate H. pylori, lifestyle changes can help manage symptoms and reduce the risk of complications. These include:

  • Eating a balanced diet: avoiding spicy, acidic, and fatty foods that can irritate the stomach.
  • Avoiding NSAIDs: nonsteroidal anti-inflammatory drugs can worsen stomach irritation.
  • Reducing stress: managing stress through techniques like mindfulness and relaxation can help alleviate symptoms.

How can I reduce my risk of H. pylori infection?

To reduce the risk of H. pylori infection, practice good hygiene, such as washing hands thoroughly with soap and water, eating food that has been properly prepared and cooked, and drinking water from a safe, clean source.

Where can I find more information about H. pylori and babA?

For more information about H. pylori and the babA virulence factor, consider consulting:

  • Healthcare providers: medical professionals can provide personalized advice and treatment options.
  • Scientific literature: research articles and reviews on H. pylori and virulence factors.
  • Reputable health organizations: websites of organizations such as the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC).

Order H. pylori and Virulence Factor Testing

Click here to compare testing options and order tests for H. pylori.

What's 
H. pylori Virulence Factor babA
?
If Your Levels Are High
Symptoms of High Levels
If Your Levels are Low
Symptoms of Low Levels

Hey Practitioners! On December 11th, join Dr. Terry Wahls in a free live class where she'll share her groundbreaking methods for managing MS and autoimmune patients. This live session will address your most pressing questions and will take a closer look at treatment options beyond the conventional standards of care. Register here.

Register Here
See References

[1.] Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019 Nov 19;11(11):677. doi: 10.3390/toxins11110677. PMID: 31752394; PMCID: PMC6891454.

[2.] Chakrani, Z., Robinson, K. & Taye, B. Association Between ABO Blood Groups and Helicobacter pylori Infection: A Meta-Analysis. Sci Rep 8, 17604 (2018). https://doi.org/10.1038/s41598-018-36006-x

[3.] Chang, WL., Yeh, YC. & Sheu, BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci 25, 68 (2018). https://doi.org/10.1186/s12929-018-0466-9

[4.] Connor B. Helicobacter Pylori | CDC Yellow Book 2024. wwwnc.cdc.gov. Published 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/helicobacter-pylori

[5.] Deng R, Chen X, Zhao S, Zhang Q, Shi Y. The effects and mechanisms of natural products on Helicobacter pylori eradication. Frontiers in cellular and infection microbiology. 2024;14. doi:https://doi.org/10.3389/fcimb.2024.1360852

[6.] Donelli LC Gianfranco. Virulence Factors of Helicobacter pylori. Microbial Ecology in Health and Disease. 2000;12(2):259-262. doi:https://doi.org/10.1080/089106000750060512

[7.] Doohan D, Rezkitha YAA, Waskito LA, Yamaoka Y, Miftahussurur M. Helicobacter pylori BabA–SabA Key Roles in the Adherence Phase: The Synergic Mechanism for Successful Colonization and Disease Development. Toxins. 2021;13(7):485. doi:https://doi.org/10.3390/toxins13070485

[8.] Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023). https://doi.org/10.1038/s41572-023-00431-8

[9.] Parikh NS, Ahlawat R. Helicobacter Pylori. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534233/

[10.] Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis. 2013 Jul;14(7):341-9. doi: 10.1111/1751-2980.12054. PMID: 23452293; PMCID: PMC3721066.

[11.] Thorell, K., Muñoz-Ramírez, Z.Y., Wang, D. et al. The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes. Nat Commun 14, 8184 (2023). https://doi.org/10.1038/s41467-023-43562-y

Test for

H. pylori Virulence Factor babA

Order, track, and receive results from 30+ labs in one place.